Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genzyme | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Genzyme

During the quarter, the company ceased fill/finish operations at its Allston facility for products sold in the U.S.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme

4Q Revenues: $1.2 billion (+23%)

4Q Earnings: $471.9 million (earnings were $23.2 million 4Q10)

FY Revenues: $4.0 billion (+2%)

FY Earnings: $422.1 million (flat)

Comments: During the quarter, the company ceased fill/finish operations at its Allston facility for products sold in the U.S. According to the company, the recovery of Cerezyme supply is on track, and Fabrazyme supply is improving with allocations up 82% from the third to fourth quarter. Cerezyme sales in the quarter were up 111% to $222.0 million. Fabrazyme sales were up 6% to $61.6 million. Myozyme sales were up 39% to $127.5 million. For the year Cerezyme sales were down 9% and Fabrazyme were down 56%. Myozyme sales for the year were up 27%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics